We are live on ! Find out more
LCM

Lynx1 Capital Management Portfolio holdings

AUM $866M
1-Year Est. Return 231.68%
This Fund
S&P 500
This Quarter Est. Return
+23.16%
1 Year Est. Return
+231.68%
3 Year Est. Return
+883.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$494M
AUM Growth
+$2.7M
Cap. Flow
-$70.8M
Cap. Flow %
-14.34%
Top 10 Hldgs %
97.17%
Holding
27
New
13
Increased
5
Reduced
1
Closed
5

Top Buys

Rank Stock Value
1
CGEM icon
Cullinan Oncology
CGEM
+$28.8M
2
DNLI icon
Denali Therapeutics
DNLI
+$24.9M
3
GHRS icon
GH Research
GHRS
+$24.6M
4
KRRO icon
Korro Bio
KRRO
+$15.8M
5
XNCR icon
Xencor
XNCR
+$10.5M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$144M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$46.5M
3
ADCT icon
ADC Therapeutics
ADCT
+$5.3M
4
IBIO icon
iBio
IBIO
+$874K
5
ALLO icon
Allogene Therapeutics
ALLO
+$677K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
1
Stoke Therapeutics
STOK
$2.02B
$172M 34.73%
5,404,674
– –
GHRS icon
2
GH Research
GHRS
$1.94B
$132M 26.75%
10,406,575
+1,805,386
+21% +$24.6M
CGEM icon
3
Cullinan Oncology
CGEM
$1.26B
$92.8M 18.78%
8,963,500
+3,197,410
+55% +$28.8M
DNLI icon
4
Denali Therapeutics
DNLI
$3.97B
$28.7M 5.81%
1,738,750
+1,477,063
+564% +$24.9M
CCCC icon
5
C4 Therapeutics
CCCC
$502M
$13.6M 2.74%
7,098,133
– –
XNCR icon
6
Xencor
XNCR
$1.71B
$10.8M 2.19%
+705,558
New +$10.5M
IMTX icon
7
Immatics
IMTX
$1.31B
$9.68M 1.96%
+921,950
New +$9.3M
TCRX icon
8
TScan Therapeutics
TCRX
$52.3M
$8.02M 1.62%
8,019,148
+161,801
+2% +$234K
PASG icon
9
Passage Bio
PASG
$14.7M
$7.36M 1.49%
623,704
– –
KRRO icon
10
Korro Bio
KRRO
$196M
$5.43M 1.1%
+677,915
New +$15.8M
DTIL icon
11
Precision BioSciences
DTIL
$201M
$4.13M 0.84%
993,913
-48,683
-5% -$276K
NEUP
12
Neuphoria Therapeutics
NEUP
$20.7M
$3.4M 0.69%
+875,228
New +$6.22M
AGIO icon
13
Agios Pharmaceuticals
AGIO
$2B
$2.17M 0.44%
+79,624
New +$2.79M
CGON icon
14
CG Oncology
CGON
$6.62B
$1.31M 0.27%
+31,591
New +$1.31M
ARWR icon
15
Arrowhead Research
ARWR
$12.1B
$800K 0.16%
+12,043
New +$590K
DSGN icon
16
Design Therapeutics
DSGN
$901M
$652K 0.13%
69,516
+3,562
+5% +$27.9K
TRDA icon
17
Entrada Therapeutics
TRDA
$290M
$531K 0.11%
+51,689
New +$436K
HOWL icon
18
Werewolf Therapeutics
HOWL
$18.8M
$416K 0.08%
+655,926
New +$797K
MPLT
19
MapLight Therapeutics
MPLT
$525M
$237K 0.05%
+13,477
New +$226K
GBIO
20
DELISTED
Generation Bio
GBIO
$142K 0.03%
+25,000
New +$141K
PRQR icon
21
ProQR Therapeutics
PRQR
$261M
$138K 0.03%
+68,486
New +$160K
APLT
22
DELISTED
Applied Therapeutics
APLT
$41K 0.01%
+410,500
New +$261K
ADCT icon
23
ADC Therapeutics
ADCT
$134M
– –
-1,325,848
Closed -$5.3M
ALLO icon
24
Allogene Therapeutics
ALLO
$683M
– –
-546,119
Closed -$677K
IBIO icon
25
iBio
IBIO
$69.5M
– –
-1,055,897
Closed -$874K
1
2

Similar funds

OMG
One Madison Group New York $866M AUM 33.81% 1-Year Est. Return
WFAL
Wedbush Fund Advisers, LLC Pasadena, California $863M AUM
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
WCM
Wallace Capital Management Dallas, Texas $871M AUM 13.69% 1-Year Est. Return
BCM
Benchstone Capital Management New York $860M AUM 32.46% 1-Year Est. Return
F1I
Fund 1 Investments Rincon, Puerto Rico $872M AUM 50.95% 1-Year Est. Return
SA
SoftVest Advisors Abilene, Texas $872M AUM 28.76% 1-Year Est. Return
OAM
Ophir Asset Management Sydney, Australia $859M AUM 59.08% 1-Year Est. Return

Lynx1 Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Lynx1 Capital Management held 27 positions worth $494M, up 0.55% from $491M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Lynx1 Capital Management withdrew a net $70.8M in Q4 2025, closing 5 positions and reducing 1 holding. Its most notable exit was Merus, an estimated $144M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Lynx1 Capital Management opened a new position in Korro Bio worth $5.43M.

  • Lynx1 Capital Management's largest Q4 2025 buy was Korro Bio: 677,915 shares worth $5.43M.
  • Lynx1 Capital Management added most to Cullinan Oncology in Q4 2025, an estimated $28.8M increase.
  • Lynx1 Capital Management's biggest Q4 2025 reduction was Precision BioSciences, cutting an estimated $276K.
  • Lynx1 Capital Management fully exited Merus in Q4 2025, selling an estimated $144M.
  • Lynx1 Capital Management's ten largest holdings make up 97% of its $494M portfolio in Q4 2025.
  • Lynx1 Capital Management opened 13 new positions and closed 5 in Q4 2025.
  • Lynx1 Capital Management's portfolio value rose 0.55% quarter-over-quarter to $494M.

Based on Lynx1 Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.